164 related articles for article (PubMed ID: 6639094)
1. [Combination therapy of vinca alkaloids and nicardipine in non-Hodgkin's lymphoma with resistant to various antineoplastic agents].
Honda T; Sampi K; Hattori M
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2330-4. PubMed ID: 6639094
[TBL] [Abstract][Full Text] [Related]
2. [Combination chemotherapy of nicardipine and vindesine sulfate, cis-diammine dichloroplatinum (II) for patients with advanced esophageal carcinoma].
Akazawa S; Honda T; Sampi K; Futatsuki K
Gan To Kagaku Ryoho; 1984 Apr; 11(4):943-7. PubMed ID: 6539096
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of vinzolidine, an oral vinca alkaloid, in Hodgkin's disease and non-Hodgkin's lymphoma.
Takasugi BJ; Jones SE; Robertone AB
Cancer Treat Rep; 1984 Nov; 68(11):1399-401. PubMed ID: 6498855
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. [Cancer chemotherapy combined with a calcium antagonist in patients with hematologic malignancies and solid tumors resistant to standard chemotherapy].
Sampi K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):951-5. PubMed ID: 3471183
[TBL] [Abstract][Full Text] [Related]
6. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
7. A review of mitomycin regimens in advanced breast cancer therapy.
Legha SS
Clin Ther; 1985; 7(3):286-307. PubMed ID: 3888391
[TBL] [Abstract][Full Text] [Related]
8. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy.
Kris MG; Pablo D; Gralla RJ; Burke MT; Prestifilippo J; Lewin D
Cancer Treat Rep; 1984; 68(7-8):1029-31. PubMed ID: 6744336
[TBL] [Abstract][Full Text] [Related]
9. MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity.
Ozols RF; Hogan WM; Ostchega Y; Young RC
Cancer Treat Rep; 1983; 67(7-8):721-2. PubMed ID: 6871888
[TBL] [Abstract][Full Text] [Related]
10. [Cis-dichlorodiammineplatinum (II) in the treatment of a refractory non-Hodgkin's lymphoma with renal involvement].
Sueyama H; Sakai K
Gan To Kagaku Ryoho; 1985 Jan; 12(1):144-6. PubMed ID: 4038445
[TBL] [Abstract][Full Text] [Related]
11. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
Coleman M; Leonard J; Shuster MW; Kaufman TP
Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
[TBL] [Abstract][Full Text] [Related]
12. [MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2005 Dec; 24(12):1503-6. PubMed ID: 16351801
[TBL] [Abstract][Full Text] [Related]
13. Vindesine, carmustine, doxorubicin, and prednisone (EBAP) in recurrent lymphomas: a Southwest Oncology Group study.
Weick JK; Jones SE; Grozea PN; Fabian CJ; Dixon DO
Cancer Treat Rep; 1984; 68(7-8):963-7. PubMed ID: 6744347
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant chemotherapy for localized non-Hodgkin's lymphoma with CVP therapy].
Horikoshi N; Inagaki J; Ogawa M
Gan To Kagaku Ryoho; 1983 Aug; 10(8):1878-84. PubMed ID: 6683953
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
19. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
20. [Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma].
Niitsu N; Hara A; Umeda M; Shirai T
Rinsho Ketsueki; 1993 Jul; 34(7):829-34. PubMed ID: 7689661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
